Latest Prostate-specific antigen Stories
A new study shows novel PSA velocity (PSAV) risk count testing may provide a more effective way for physicians to screen men for clinically significant prostate cancer.
Physicians advising men whether to be screened for prostate cancer with a PSA test must rely more on available evidence when recommending screening, biopsies and treatments rather than long held beliefs that PSA-based testing is beneficial for all, Beth Israel Deaconess Medical Center prostate expert Marc B. Garnick, MD, says.
For men diagnosed with low-risk, localized prostate cancer, being treated with the drug dutasteride ("Avodart") delays disease progression and initiating active treatment, and also reduces anxiety, show the results of a three-year international clinical trial led by Dr. Neil Fleshner, Head of the Division of Urology, University Health Network (UHN).
- Withering but not falling off, as a blossom that persists on a twig after flowering.